BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended June 30, 2025. “This quarter, we made further progress in the development of our promising myotonic dystrophy type 1 program, PGN-EDODM1. With class-leading mean mis-
Related Questions
What was the nature of any recent collaborations, licensing deals, or partnerships announced, and how could they affect the company's valuation?
What were PepGen's revenue, net loss, and cash position for Q2 2025, and how do they compare to analyst consensus estimates?
What is the current cash runway and burn rate, and when does the company expect to need additional financing?
What are the analyst coverage changes or target price revisions following this earnings release?
What are the key risks and uncertainties associated with the ongoing clinical trials for PGN-EDODM1?
What is the market’s perception of PepGen's competitive position within the neuromuscular and neurological disease space?
How might upcoming FDA or regulatory milestones for the oligonucleotide platform affect short‑term price volatility?
How does PepGen's Q2 2025 performance compare to the same quarter in 2024 and to its peer biotech companies?
How significant is the progress reported for the PGN-EDODM1 myotonic dystrophy program in terms of clinical milestones and potential market impact?
Did the company provide any guidance for Q3 2025 or full-year 2025 revenue, expenses, or milestones, and how does it align with market expectations?